Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 10, 2020
Daily News
September 10, 2020
- Japan to Require Pledges from Troubled Generic Makers to Skip Next Listing Round If Supply Issues Occur Again
September 10, 2020
- RegeNephron, Kirin Join Hands on Cell Therapy Process Development
September 10, 2020
- Label Revisions Ordered for Plaquenil, Relumina
September 10, 2020
- Takeda to Divest Non-Core Products Sold in Europe, Canada to Cheplapharm
September 10, 2020
- Japan Scrambles to Collect Info on AstraZeneca Vaccine Trial Pause, Sticks to 2021 H1 Immunization Goal
September 10, 2020
- MHLW Erases Hydroxychloroquine, 4 Other Drugs from COVID-19 Treatment Guide
September 10, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…